SMTI vs. RXST, FNA, BFLY, ESTA, EYE, BBNX, EMBC, BVS, AXGN, and CBLL
Should you be buying Sanara MedTech stock or one of its competitors? The main competitors of Sanara MedTech include RxSight (RXST), Paragon 28 (FNA), Butterfly Network (BFLY), Establishment Labs (ESTA), National Vision (EYE), Beta Bionics (BBNX), Embecta (EMBC), Bioventus (BVS), AxoGen (AXGN), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.
Sanara MedTech vs.
RxSight (NASDAQ:RXST) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations.
RxSight currently has a consensus target price of $58.13, suggesting a potential upside of 96.37%. Sanara MedTech has a consensus target price of $47.00, suggesting a potential upside of 39.51%. Given RxSight's higher possible upside, equities analysts clearly believe RxSight is more favorable than Sanara MedTech.
RxSight received 26 more outperform votes than Sanara MedTech when rated by MarketBeat users. Likewise, 68.12% of users gave RxSight an outperform vote while only 58.33% of users gave Sanara MedTech an outperform vote.
78.8% of RxSight shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 9.4% of RxSight shares are held by insiders. Comparatively, 54.1% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, RxSight had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for RxSight and 0 mentions for Sanara MedTech. RxSight's average media sentiment score of 0.54 beat Sanara MedTech's score of 0.00 indicating that RxSight is being referred to more favorably in the media.
Sanara MedTech has a net margin of -10.71% compared to RxSight's net margin of -23.92%. RxSight's return on equity of -14.00% beat Sanara MedTech's return on equity.
Sanara MedTech has lower revenue, but higher earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.
RxSight has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
Summary
RxSight beats Sanara MedTech on 11 of the 18 factors compared between the two stocks.
Get Sanara MedTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sanara MedTech Competitors List
Related Companies and Tools
This page (NASDAQ:SMTI) was last updated on 2/22/2025 by MarketBeat.com Staff
Free SMTI Stock Alerts